Pune, Maharashtra, India, June 2025 — Nitin Shetty has been appointed as the President of INTOX Pvt. Ltd., the safety assessment division of Aragen Life Sciences, further reinforcing the company’s leadership in integrated drug discovery, development, and manufacturing solutions. With an illustrious career spanning more than three decades in toxicology, DMPK (drug metabolism and pharmacokinetics), and regulatory sciences, Dr. Shetty’s elevation marks a strategic step in advancing Aragen’s preclinical service capabilities for global life sciences clients.
In his new role, Dr. Shetty will lead the scientific and operational roadmap of INTOX, with a strong emphasis on delivering excellence in safety pharmacology, bioanalytical research, and regulatory toxicology studies. His appointment reflects Aragen’s commitment to scaling innovation, operational efficiency, and global scientific partnerships in the preclinical CRO space.
Before joining INTOX, Dr. Shetty served as Chief Technical Officer at Bioneeds India Private Limited, where for nearly eight years, he spearheaded preclinical strategy and regulatory initiatives for drug discovery and development. Under his leadership, Bioneeds strengthened its positioning as a full-spectrum CRO delivering high-impact solutions to pharmaceutical and biotech clients.
Previously, he held the role of Vice President – Preclinical at Vimta Labs, contributing significantly to expanding the lab’s toxicology and safety sciences practice. His earlier stints include more than a decade at Wockhardt Ltd. as Head of Toxicology, where he led multiple safety evaluation programs, and leadership roles at Ranbaxy Laboratories and Jai Research Foundation, where he laid the foundation for his pioneering work in new chemical entity (NCE) evaluation and translational toxicology.
Dr. Shetty’s extensive cross-sector experience—from pharmaceuticals and biotech to agrochemicals and industrial safety—makes him a uniquely qualified leader to guide INTOX’s next phase of growth.
INTOX Pvt. Ltd.
Established in 1995 and based near Pune, INTOX is a leading Indian contract research organization specializing in toxicology, bioanalytical studies, mutagenicity, environmental toxicity, and regulatory sciences. It has been OECD GLP certified by the Indian and Netherlands GLP Monitoring Authorities since 2007. In December 2021, INTOX was acquired by Aragen Life Sciences, positioning it as a core pillar in Aragen’s fully integrated CRO/CDMO platform for global drug discovery and development.
Read Also : HR Is Not a Support Function—It’s the CEO’s Most Powerful Growth Engine
The Fine Balance: Navigating Work, Life, and Mental Wellbeing
From Gatekeeping to Gateway Building: Transforming How Organisations Create Access
Leadership In Talent Management: A Powerful Driver for Economic Growth
